At the time of writing, Tenaya Therapeutics Inc [TNYA] stock is trading at $0.63, up 17.37%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The TNYA shares have gain 37.78% over the last week, with a monthly amount glided 40.88%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Leerink Partners started tracking the stock with Outperform rating on November 30, 2023, and set its price target to $7. On June 15, 2022, H.C. Wainwright initiated with a Buy rating and assigned a price target of $25 on the stock.
For the past year, the stock price of Tenaya Therapeutics Inc fluctuated between $0.36 and $4.06. Tenaya Therapeutics Inc [NASDAQ: TNYA] shares were valued at $0.63 at the most recent close of the market.
Analyzing the TNYA fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.73, Equity is -0.92 and Total Capital is -0.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.11.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5776 points at the first support level, and at 0.5213 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.6625, and for the 2nd resistance point, it is at 0.6911.
Ratios To Look Out For
It is important to note that Tenaya Therapeutics Inc [NASDAQ:TNYA] has a current ratio of 6.68. Further, the Quick Ratio stands at 6.68, while the Cash Ratio is 3.8.
Transactions by insiders
Recent insider trading involved Higa Tomohiro, SVP, Finance, that happened on May 16 ’25 when 1390.0 shares were sold. Chief Medical Officer, Tingley Whittemore completed a deal on May 16 ’25 to sell 2937.0 shares. Meanwhile, Chief Executive Officer Ali Faraz sold 3189.0 shares on May 16 ’25.
